Method of treating cancer with an hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
AssigneeInternational Institute of Cancer Immunology, Inc.
InventorHaruo SUGIYAMA
Life of this patent
Estimating the term…
Abstract
Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.
Claims17
-20. (canceled)
A method for the treatment of cancer in an HLA-A*3303 positive subject, comprising administering to the subject a peptide comprising Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No:
- 3).
A method for the treatment of cancer in an HLA-A*3303 positive subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide comprising Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No:
- 3).
Dependencies are inferred from the claim text.